IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
Recombinant pertussis booster vaccines provided sustained immunity against whooping cough in adolescents and young adults, ...
Recombinant antibody technology has helped address many problems associated with hybridoma platforms, opening the door to a ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global ...
Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...
Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...
Ocular MG is marked by lower AChR antibody titers and a milder phenotype, and responds more quickly to less aggressive ...
By Charles Buchanan For people living with autoimmune diseases, their condition can cast a constant shadow over nearly every ...
Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new ...
MedPage Today brought together three expert leaders in the field: Moderator Joseph Mikhael, MD, is joined by Amrita Krishnan, MD, and Tulio Rodriguez, MD, all of City of Hope, for a virtual roundtable ...
About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...